Logo

BioNTech Signs an Agreement with Gates Foundation to Develop Therapies for HIV and Tuberculosis

Share this

BioNTech Signs an Agreement with Gates Foundation to Develop Therapies for HIV and Tuberculosis

Shots:

  • Gates Foundation to fund $55M which may extend up to $100M for the development of preclinical vaccine and immunotherapy candidates preventing HIV and tuberculosis infection. BioNTech will retain rights to commercialize candidates in developed countries while providing affordable access to the candidates in developing countries
  • The agreements will further expand the BioNTech’s infectious disease portfolio with the initiation of three new additional programs to be developed utilizing BioNTech’s mRNA platforms
  • BioNTech’s infectious diseases candidates contain modified mRNA-encoding antigens specific to a target pathogen- thus resulting in activation of T cells & B cells for fighting against pathogen

Click here to­ read full press release/ article | Ref: BioNTech | Image: : BioNTech    


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions